MACROGENICS, INC. (MGNX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
39/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinMGNX / S&P 59.86% / 15.20% |
LoseMGNX / S&P 11.69% / 15.00% |
LoseMGNX / S&P -61.40% / 50.40% |
| 2026-Q11/3 |
WinMGNX / S&P 79.50% / -4.33% |
LoseMGNX / S&P -8.01% / 11.30% |
LoseMGNX / S&P 23.60% / 27.70% |
| 2025-Q40/3 |
LoseMGNX / S&P -4.17% / 2.65% |
LoseMGNX / S&P -10.56% / 9.00% |
LoseMGNX / S&P 8.33% / 13.40% |
| 2025-Q31/3 |
WinMGNX / S&P 38.84% / 8.12% |
LoseMGNX / S&P -20.57% / 4.61% |
LoseMGNX / S&P -24.05% / 13.45% |
| 2025-Q21/3 |
LoseMGNX / S&P -4.72% / 10.94% |
WinMGNX / S&P 265.99% / 4.83% |
LoseMGNX / S&P -74.09% / 10.63% |
| 2025-Q12/3 |
LoseMGNX / S&P -60.92% / -4.27% |
WinMGNX / S&P 255.31% / 4.98% |
WinMGNX / S&P 128.21% / 10.57% |
| 2024-Q42/3 |
LoseMGNX / S&P -1.22% / 2.41% |
WinMGNX / S&P 155.26% / 5.25% |
WinMGNX / S&P 575.00% / 6.15% |
| 2024-Q31/3 |
LoseMGNX / S&P -22.59% / 5.89% |
WinMGNX / S&P 16.68% / 5.89% |
LoseMGNX / S&P -297.50% / 6.11% |
| 2024-Q20/3 |
LoseMGNX / S&P -71.13% / 4.28% |
LoseMGNX / S&P -73.10% / 5.38% |
LoseMGNX / S&P -1933.33% / 5.12% |
| 2024-Q11/3 |
WinMGNX / S&P 53.01% / 10.56% |
LoseMGNX / S&P -73.78% / 5.71% |
LoseMGNX / S&P -73.47% / 5.59% |
| 2023-Q41/3 |
WinMGNX / S&P 106.44% / 11.69% |
LoseMGNX / S&P -61.33% / 6.81% |
LoseMGNX / S&P -91.75% / 7.78% |
| 2023-Q31/3 |
LoseMGNX / S&P -12.90% / -3.27% |
WinMGNX / S&P 30.26% / 7.52% |
LoseMGNX / S&P -125.81% / -5.03% |
| 2023-Q21/3 |
LoseMGNX / S&P -25.38% / 8.74% |
WinMGNX / S&P 127.84% / 9.50% |
LoseMGNX / S&P -103.37% / -8.57% |
| 2023-Q11/3 |
LoseMGNX / S&P 6.86% / 7.50% |
WinMGNX / S&P 130.70% / 10.77% |
LoseMGNX / S&P -58.59% / -15.69% |
| 2022-Q42/3 |
WinMGNX / S&P 93.93% / 7.56% |
WinMGNX / S&P 96.19% / 11.88% |
LoseMGNX / S&P -42.43% / -17.99% |
| 2022-Q32/3 |
WinMGNX / S&P 17.29% / -4.88% |
LoseMGNX / S&P -19.83% / 13.47% |
WinMGNX / S&P 29.17% / -1.41% |
| 2022-Q21/3 |
LoseMGNX / S&P -66.52% / -16.10% |
LoseMGNX / S&P -43.57% / 13.71% |
WinMGNX / S&P 61.82% / 11.04% |
| 2022-Q11/3 |
LoseMGNX / S&P -45.11% / -4.60% |
LoseMGNX / S&P -33.69% / 15.97% |
WinMGNX / S&P 43.15% / 42.23% |
| 2021-Q40/3 |
LoseMGNX / S&P -23.35% / 11.03% |
LoseMGNX / S&P -26.16% / 15.00% |
LoseMGNX / S&P MGNX unavailable / 96.40% |
| 2021-Q31/3 |
LoseMGNX / S&P -22.04% / 0.58% |
WinMGNX / S&P 49.89% / 10.77% |
LoseMGNX / S&P MGNX unavailable / 69.42% |
| 2021-Q21/3 |
LoseMGNX / S&P -15.67% / 8.55% |
WinMGNX / S&P 52.28% / 6.58% |
LoseMGNX / S&P MGNX unavailable / 51.81% |
| 2021-Q12/3 |
WinMGNX / S&P 39.33% / 6.17% |
WinMGNX / S&P 58.46% / -1.06% |
LoseMGNX / S&P MGNX unavailable / 7.39% |
| 2020-Q41/3 |
LoseMGNX / S&P -9.25% / 12.15% |
WinMGNX / S&P 63.40% / -3.72% |
LoseMGNX / S&P MGNX unavailable / -33.42% |
| 2020-Q31/3 |
LoseMGNX / S&P -9.78% / 8.93% |
WinMGNX / S&P 41.24% / -2.04% |
LoseMGNX / S&P MGNX unavailable / -27.10% |
| 2020-Q22/3 |
WinMGNX / S&P 379.73% / 20.54% |
WinMGNX / S&P 36.99% / -0.46% |
LoseMGNX / S&P MGNX unavailable / -27.11% |
| 2020-Q11/3 |
LoseMGNX / S&P -46.51% / -19.60% |
WinMGNX / S&P 4.79% / 3.47% |
LoseMGNX / S&P MGNX unavailable / -14.75% |
| 2019-Q41/3 |
LoseMGNX / S&P -14.73% / 9.07% |
WinMGNX / S&P 6.76% / 5.36% |
LoseMGNX / S&P MGNX unavailable / 2.99% |
| 2019-Q30/3 |
LoseMGNX / S&P -24.81% / 1.70% |
LoseMGNX / S&P -72.14% / 5.02% |
LoseMGNX / S&P MGNX unavailable / 0.21% |
| 2019-Q20/3 |
LoseMGNX / S&P -5.62% / 4.30% |
LoseMGNX / S&P -67.98% / 6.64% |
LoseMGNX / S&P MGNX unavailable / 8.65% |
| 2019-Q11/3 |
WinMGNX / S&P 41.57% / 13.65% |
LoseMGNX / S&P -59.42% / 8.12% |
LoseMGNX / S&P MGNX unavailable / 14.29% |
| 2018-Q40/3 |
LoseMGNX / S&P -40.76% / -13.52% |
LoseMGNX / S&P -61.89% / 9.05% |
LoseMGNX / S&P MGNX unavailable / 18.23% |
| 2018-Q31/3 |
LoseMGNX / S&P 3.83% / 7.71% |
WinMGNX / S&P 1774.99% / 10.21% |
LoseMGNX / S&P MGNX unavailable / 19.06% |
| 2018-Q21/3 |
LoseMGNX / S&P -17.93% / 3.43% |
WinMGNX / S&P 1369.55% / 9.03% |
LoseMGNX / S&P MGNX unavailable / 14.46% |
| 2018-Q12/3 |
WinMGNX / S&P 32.42% / -0.76% |
WinMGNX / S&P 76.07% / 7.68% |
LoseMGNX / S&P MGNX unavailable / 12.46% |
| 2017-Q41/3 |
LoseMGNX / S&P 2.81% / 6.64% |
WinMGNX / S&P 71.68% / 7.03% |
LoseMGNX / S&P MGNX unavailable / 13.82% |
| 2017-Q31/3 |
WinMGNX / S&P 5.54% / 4.48% |
LoseMGNX / S&P -88.95% / 5.68% |
LoseMGNX / S&P MGNX unavailable / 17.57% |
| 2017-Q20/3 |
LoseMGNX / S&P -5.86% / 3.09% |
LoseMGNX / S&P -88.64% / 4.83% |
LoseMGNX / S&P MGNX unavailable / 17.74% |
| 2017-Q11/3 |
LoseMGNX / S&P -9.00% / 6.07% |
WinMGNX / S&P 180.96% / 3.67% |
LoseMGNX / S&P MGNX unavailable / 13.32% |
| 2016-Q40/3 |
LoseMGNX / S&P -31.66% / 3.82% |
LoseMGNX / S&P -8.90% / 2.09% |
LoseMGNX / S&P MGNX unavailable / 7.05% |
| 2016-Q31/3 |
WinMGNX / S&P 10.82% / 3.85% |
LoseMGNX / S&P -3.26% / 0.20% |
LoseMGNX / S&P MGNX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | MGNX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 130.51% | 20.78% |
| Annualized return | 130.51% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | MGNX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.86% | 83.14% |
| Annualized return | -29.72% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | MGNX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -86.42% | 319.30% |
| Annualized return | -18.10% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |